|
|
|
Welcome to the Quality Counts. For those health conscious consumers and medical professionals that are looking to purchase nutritional supplements, vitamins, herbs, learning about medications, losing weight, health food, low carbs, high protein nutrition, and exercise, you have come to the right place. Quality Counts serves both the medical practitioner and consumer interested in nutritional therapy and alternative medicine.
Home > Health Conditions > Diabetes >
Diabeta (glyburide)
Diabeta, Micronase (glyburide/glibenclamide)
Related Topics:
News & Research:
-
Glyburide - rxlsit.com -
"Glyburide appears to lower the blood glucose acutely by stimulating the
release of insulin from the pancreas, an effect dependent upon functioning
beta cells in the pancreatic islets"
- Glyburide a Risk
for Diabetes Patients With Emergent PCI?: Glyburide Increases Risk in
Patients With Diabetes Mellitus After Emergent Percutaneous Intervention for
Myocardial Infarction – A Nationwide Study - Medscape, 11/28/11 -
"The adjusted Cox models showed an increased risk
for cardiovascular mortality with glyburide (hazard ratio [HR], 2.91; 95%
confidence interval [CI] 1.26-6.72; P = .012) compared with metformin. The
risk for cardiovascular mortality and nonfatal MI (HR, 2.69; CI, 1.21-6.00;
P = .016) and the risk for all-cause mortality (HR, 2.46; CI, 1.11-5.47; P =
.027) were also increased in patients receiving glyburide"
-
PERISCOPE Analysis Highlights TZD Lipid Effects - Medscape, 1/10/11 -
"In that randomized comparison of the
thiazolidinedione (TZD) vs glimepiride(Amaryl, Sanofi-Aventis) in patients
with diabetes [2], those taking the TZD saw significantly less coronary
disease progression as assessed with intravascular ultrasound (IVUS) over 18
months compared with those taking the other drug, a sulfonylurea. They also
benefited with steeper declines in fasting insulin and blood glucose levels,
glycated hemoglobin (HbA1C), C-reactive protein (CRP), and triglycerides as
well as improved HDL-cholesterol levels ... the post hoc analysis "ties
nicely" with the 2006 CHICAGOstudy, in which elevations in HDL were the most
important predictor of reduced progression of carotid intima-media
thickness"
-
Pioglitazone vs glimepiride: Differential effects on vascular endothelial
function in patients with type 2 diabetes - Atherosclerosis. 2008 Dec 6
- "In patients with type 2 diabetes already on
metformin, addition of pioglitazone as compared to glimepiride, improved
endothelial function despite similar glycemic control. The improvement in
endothelial function was mainly due to a reduction in insulin resistance"
-
Diabetes Drugs
Compared - WebMD, 12/6/06 -
"Avandia had the lowest treatment failure rate -- 15% -- compared with 21%
for Glucophage and 34% for Micronase"
-
Long-term Safety of Pioglitazone vs Glyburide for Type 2 Diabetes -
Medscape, 12/1/06 - "Patients with
type 2 diabetes mellitus achieve glycemic control safely and effectively
with both pioglitazone and glyburide treatment; however, the results of this
study suggest that long-term treatment with pioglitazone is superior to
glyburide with respect to tolerability. Overall, pioglitazone treatment
resulted in sustained glycemic control, fewer patient withdrawals due to
lack of efficacy or hypoglycemia, and fewer cardiac events compared with
glyburide"
- Metformin-Glibenclamide Combination Is More Effective Than Monotherapy In Type 2 Diabetes - Doctor's Guide, 4/24/03
-
Glyburide/Metformin Combination Effective For Type 2 Diabetes Inadequately Controlled By Sulphonylurea - Doctor's Guide, 2/3/02
Abstracts:
-
Glycemic
Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy - N Engl J
Med. 2006 Dec 4- "Kaplan-Meier analysis showed
a cumulative incidence of monotherapy failure at 5 years of 15% with
rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a
risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as
compared with glyburide (P<0.001 for both comparisons). The difference in the
durability of the treatment effect was greater between rosiglitazone and
glyburide than between rosiglitazone and metformin. Glyburide was associated
with a lower risk of cardiovascular events (including congestive heart failure)
than was rosiglitazone (P<0.05), and the risk associated with metformin was
similar to that with rosiglitazone. Rosiglitazone was associated with more
weight gain and edema than either metformin or glyburide but with fewer
gastrointestinal events than metformin and with less hypoglycemia than
glyburide"
-
Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome - Endocrine 2003 Apr;20(3):215-8 -
"CRP level was significantly lower in patients using metformin for blood glucose control compared with those using glibenclamide,
5.56 and 8.3 mg/L, respectively ... The data showed that metformin decreases the level of circulating CRP, a marker of inflammation, more than glibenclamide"
Related Sites:
70526
|
